Clinical IntelligenceReedley Review
A medication review, assembled before you start.
Medicines, indications, results, allergies, letters and monitoring are gathered into one structured brief with sources; you edit it, write the review and record it as yours.
Interactive demonstration
Synthetic patient · pause, step and replay at any point
A structured medication review prepared from the synthetic record, each line with its source. The medication review brief is not in the development build. Copy-out only; nothing is written to any record.
Daniel OKONKWO NHS 999 000 0115
Born 02 Nov 1961 · 65 y · male · Record as of 12 Nov 2026 10:30
A structured medication review prepared from the synthetic record, each line with its source. The medication review brief is not in the development build. Copy-out only; nothing is written to any record.
Step 1 of 10 · Review opened · Continues as you scroll
- Review opened
- Medicines gathered
- Investigations and allergies
- Medication history read
- Correspondence read
- Monitoring rules read
- Review brief assembled
- Items to verify
- Follow-up questions
- Note edited and attested
Structured medication review · appointment 12 Nov 2026 10:30 · previous review 14 Nov 2025
K. AHMED, clinical pharmacist (prescriber)
Reedley work history · 2 Nov 2026 08:15Consultation · 14 Nov 2025 · K. AHMED- Medicines gathered and comparedFound · 2 sourcesCurrent medication record: found; Problem list: found
Current medication record · 5 / Problem list · 4
4 current medicines · 1 without a recorded indication
- Investigations and allergiesFound · 2 sourcesResults: found; Allergies and intolerances: found
Results · 7 / Allergies and intolerances · 1
7 results, shown as reported · 1 intolerance
- Medication historyFound · 2 sourcesMedication history: found; Consultations: found
Medication history · 8 / Consultations · 8
3 changes since the last review on 14 Nov 2025
- Specialist correspondenceFound · 2 sourcesLetter paragraphs (3 letters): found; Referrals: found
Letter paragraphs (3 letters) · 11 / Referrals · 2
3 letters · 1 difference to verify · 1 with a later reply in correspondence
- Monitoring requirementsFound · 2 sourcesPractice monitoring rules (draft · unsigned): found; Reedley work history: found
Practice monitoring rules (draft · unsigned) · 16 / Reedley work history · 16
2 medicines with a draft-rule requirement · next U&E due by 9 Nov 2027
Preparation finished · nothing has been reviewed yet
Current medicines and indications
From: Medicines gathered and compared
- Lercanidipine 10 mg once daily · hypertension (recorded)medication record · as at 12 Nov 2026
- Ramipril 10 mg once daily · hypertension (recorded)medication record · as at 12 Nov 2026
- Atorvastatin 20 mg at night · hypercholesterolaemia (recorded)medication record · as at 12 Nov 2026
- Dapagliflozin 10 mg once daily · not recorded on the medication entrymedication record · as at 12 Nov 2026
Allergies and intolerances
From: Investigations and allergies
- Codeine — nausea and vomiting (intolerance), recorded 16 Apr 2018Allergies and intolerances · recorded 16 Apr 2018
Recent investigations, as reported
From: Investigations and allergies
- 9 Nov 2026U&E · creatinine 131 µmol/L, eGFR 52 mL/min/1.73m² · no laboratory flag · review recorded 12 Nov 08:31Result · received 9 Nov 2026 15:20Reedley work history · 12 Nov 2026 08:31
- 1 Jul 2026ECG · sinus rhythm, rate 72 per minuteResult · 1 Jul 2026
- 3 Jun 2026U&E · creatinine 124 µmol/L, eGFR 56 mL/min/1.73m² · no laboratory flagResult · received 3 Jun 2026 15:48
- 3 Jun 2026Urine albumin:creatinine ratio 38 mg/mmol · flagged H by the laboratoryResult · received 3 Jun 2026 15:48
- 14 Nov 2025Lipid profile · total cholesterol 4.1 mmol/L, LDL cholesterol 2.0 mmol/L · no laboratory flagResult · received 14 Nov 2025 16:05
Values as the laboratory reported them. Reedley does not interpret results.
Changes since the last review
From: Medication history
- 22 Apr 2026Amlodipine increased from 5 mg to 10 mg once dailyMedication record · 22 Apr 2026
- 17 Jun 2026Amlodipine stopped (reason recorded: ankle oedema); lercanidipine 10 mg once daily startedMedication record · 17 Jun 2026Medication record · 17 Jun 2026
- 7 Oct 2026Dapagliflozin 10 mg once daily started, as asked by the renal clinicMedication record · 7 Oct 2026Consultation · 7 Oct 2026 · K. AHMED
Specialist correspondence
From: Specialist correspondence
- 2 Sep 2026Cardiology (Dr J. MORLEY): continue current antihypertensive treatment; clinic target below 140/90 mmHg; conditional bisoprolol sentence; no further cardiology follow-upCardiology clinic letter ¶3 · dated 2 Sep 2026Cardiology clinic letter ¶4 · dated 2 Sep 2026Cardiology clinic letter ¶5 · dated 2 Sep 2026
- 5 Oct 2026Renal clinic (Dr A. FENWICK): amlodipine instruction; dapagliflozin for chronic kidney disease with U&E 4 to 6 weeks after starting; renal review in 6 monthsRenal clinic letter ¶2 · dated 5 Oct 2026Renal clinic letter ¶3 · dated 5 Oct 2026Renal clinic letter ¶4 · dated 5 Oct 2026
- 20 Oct 2026Renal clinic reply: the 5 Oct letter was written from an out-of-date list; continue lercanidipine; blood pressure recheck in 4 weeksRenal clinic reply ¶1 · dated 20 Oct 2026Renal clinic reply ¶2 · dated 20 Oct 2026
Monitoring requirements · draft rules
From: Monitoring requirements
- Ramipril · U&E at least every 12 months · next due by 9 Nov 2027Practice monitoring rule · draft · unsignedResult · received 9 Nov 2026 15:20
- Dapagliflozin · U&E at least every 12 months · the letter’s 4 to 6 week test received 9 Nov 2026 · next due by 9 Nov 2027Practice monitoring rule · draft · unsignedRenal clinic letter ¶3 · dated 5 Oct 2026
- Atorvastatin · the draft rule covers the first 12 months after starting (started 12 Mar 2019) · no current requirementPractice monitoring rule · draft · unsignedMedication record · 12 Mar 2019
- Lercanidipine · not named in any draft rulemedication record · as at 12 Nov 2026
Practice draft rules · draft · unsigned · no named clinical owner yet. The draft rules do not yet take account of kidney function category, age or indication; a clinician sets each patient’s interval.
Open work
From: Monitoring requirements
- Structured medication review · assigned · owner K. AHMED · this appointmentReedley work history · 2 Nov 2026 08:15
- Blood pressure recheck · actioned · booked 16 Nov 09:20 · attendance not yet confirmedReedley work history · 29 Oct 2026 14:06
Documented points for the conversation
From: Monitoring requirements
Drawn only from documented facts. Reedley does not suggest changes to treatment.
- The 4 Sep note records that he will contact the practice if palpitations become troublesome.Consultation · 4 Sep 2026 · Dr S. PATEL
- Sick-day guidance for dapagliflozin was explained on 7 Oct.Consultation · 7 Oct 2026 · K. AHMED
- On 15 Jul the nurse recorded that the ankle swelling had gone.Consultation · 15 Jul 2026 · Practice nurse
Items to verify
From: Monitoring requirements
Differences between sources and gaps in the record, with the evidence for each. Each starts as not reviewed; only the clinician can mark one reviewed.
4 items to verify · none reviewed yet
Sources differ
Renal letter and medication record differ on amlodipine
The renal clinic letter dated 5 Oct asks for an amlodipine increase and lists amlodipine 5 mg in the clinic’s medication list. The record shows amlodipine stopped on 17 Jun 2026. The reply dated 20 Oct refers to lercanidipine instead.
1 with a later reply in correspondence
Renal clinic letter ¶1 · dated 5 Oct 2026Medication record · 17 Jun 2026Renal clinic reply ¶1 · dated 20 Oct 2026Not reviewedReviewed by K. AHMED · 10:52Not found in the available record
No indication on the dapagliflozin entry
The medication entry has no indication text. The renal clinic letter gives the reason for starting it.
medication record · as at 12 Nov 2026Renal clinic letter ¶3 · dated 5 Oct 2026Not reviewedReviewed by K. AHMED · 10:53Not found in the available record
No blood pressure recorded since 15 Jul 2026
The latest recorded blood pressure is 134/82 on 15 Jul 2026. A recheck is booked for 16 Nov; booked is not attended.
Consultation · 15 Jul 2026 · Practice nurseReedley work history · 29 Oct 2026 14:06Not reviewedReviewed by K. AHMED · 10:54Not found in the available record
No entry about palpitations since 4 Sep 2026
The cardiology letter’s bisoprolol sentence is conditional. The 4 Sep telephone note records his preference; no later entry mentions palpitations.
Cardiology clinic letter ¶4 · dated 2 Sep 2026Consultation · 4 Sep 2026 · Dr S. PATELNot reviewedReviewed by K. AHMED · 10:55
Follow-up questions
Has he previously been prescribed amlodipine?
Context kept: Patient: Daniel OKONKWO · this review
Yes. Amlodipine 5 mg once daily from 16 May 2022, increased to 10 mg on 22 Apr 2026, stopped on 17 Jun 2026.
Medication record · 16 May 2022Medication record · 22 Apr 2026Medication record · 17 Jun 2026What was documented about the reason for stopping it?
Context kept: “it” = amlodipine, from the previous answer
The medication record gives the reason as ankle oedema. The consultation on 17 Jun 2026 (Dr S. PATEL) records six weeks of ankle swelling since the April increase.
Medication record · 17 Jun 2026Consultation · 17 Jun 2026 · Dr S. PATELAdd the relevant history to my review notes.
Context kept: “the relevant history” = the amlodipine entries from the two previous answers
Added one line to the draft note, highlighted. Edit or remove it before copying.
Medication record · 16 May 2022Medication record · 17 Jun 2026Medication record · 17 Jun 2026Copy-out only; nothing is written to any record. Copied text starts “DRAFT · SYNTHETIC DEMONSTRATION · NOT FOR CLINICAL USE”.
Clinician attestation
I have reviewed this brief and edited the draft note.
4 items to verify · none reviewed yet
Attestation recorded · K. AHMED, clinical pharmacist (prescriber) · 12 Nov 2026 10:58
An attestation records who reviewed the brief and when. It does not verify anything and does not change a lifecycle state.
Structured medication reviewAssignedStill open: closes only when a medication review entry is read from the clinical record (Simulated).
Sources behind the brief · 36 entries and draft rules, each cited passage marked
Sources behind the brief
36 entries and draft rules, newest first · as of 12 Nov 2026 10:30
08:31 · Reedley, from the clinical record (Simulated)
Reviewed and filed by K. AHMED 12 Nov 2026 08:31. U&E item closed · completed.
Medication record · as at 12 Nov 2026
Lercanidipine 10mg tablets 10 mg once daily · indication: hypertension · last issued 2 Nov 2026
Medication record · as at 12 Nov 2026
Ramipril 10mg capsules 10 mg once daily · indication: hypertension · last issued 2 Nov 2026
Medication record · as at 12 Nov 2026
Atorvastatin 20mg tablets 20 mg at night · indication: hypercholesterolaemia · last issued 2 Nov 2026
Medication record · as at 12 Nov 2026
Dapagliflozin 10mg tablets 10 mg once daily · no indication recorded · last issued 2 Nov 2026
Northfield Pathology (fictional) · received 9 Nov 2026 15:20
U&E: Na 140 mmol/L, K 4.6 mmol/L, creatinine 131 µmol/L, eGFR 52 mL/min/1.73m² · no laboratory flag
08:15 · K. AHMED
Assigned: structured medication review · owner K. AHMED · appointment 12 Nov 10:30 (medication review date on the repeat template: 14 Nov 2026).
14:06 · Reedley (Simulated)
Booked by the patient for 16 Nov 09:20 · attendance not yet confirmed.
Dr A. FENWICK · Northfield General Hospital (fictional)
Thank you for your query of 6 October. My letter of 5 October was written from an out-of-date medication list and should have referred to lercanidipine. Please continue lercanidipine 10 mg once daily; I am not asking for any change to it.
Dr A. FENWICK · Northfield General Hospital (fictional)
I would still be grateful if his blood pressure could be rechecked in 4 weeks, as planned.
K. AHMED
Dapagliflozin 10 mg once daily started. No indication text entered.
K. AHMED
Telephone: renal clinic letter of 5 Oct discussed. Dapagliflozin 10 mg once daily started as requested in the letter; sick-day guidance explained. Amlodipine instruction queried with the renal team because he no longer takes amlodipine.
Dr A. FENWICK · Northfield General Hospital (fictional)
Please increase amlodipine to 10 mg once daily and recheck blood pressure in 4 weeks.
Dr A. FENWICK · Northfield General Hospital (fictional)
His urine albumin:creatinine ratio remains raised. I would be grateful if you could start dapagliflozin 10 mg once daily for his chronic kidney disease and check his urea and electrolytes 4 to 6 weeks after starting.
Dr A. FENWICK · Northfield General Hospital (fictional)
I will review him in the renal clinic in 6 months.
Dr A. FENWICK · Northfield General Hospital (fictional)
Seen in the renal clinic on 29 September 2026. Medication list as provided at clinic: amlodipine 5 mg once daily, ramipril 10 mg once daily, atorvastatin 20 mg at night.
Dr S. PATEL
Telephone: cardiology letter discussed. Palpitations now infrequent. Prefers not to start a new medicine at present; will contact the practice if they become troublesome.
Dr J. MORLEY · Northfield General Hospital (fictional)
I would recommend continuing his current antihypertensive treatment, aiming for a clinic blood pressure below 140/90 mmHg.
Dr J. MORLEY · Northfield General Hospital (fictional)
If the palpitations become troublesome, please consider bisoprolol 1.25 mg once daily.
Dr J. MORLEY · Northfield General Hospital (fictional)
I have not arranged further cardiology follow-up and have discharged him to the care of his GP.
Practice nurse
BP check. Ankle swelling resolved since stopping amlodipine. BP 134/82. Continue lercanidipine.
Synthetic Practice
12-lead ECG: sinus rhythm, rate 72 per minute (practice-recorded report)
Dr S. PATEL
Amlodipine stopped. Reason recorded: ankle oedema.
Dr S. PATEL
Lercanidipine 10 mg once daily started. Indication: hypertension.
Dr S. PATEL
Ankle swelling both legs for 6 weeks since amlodipine increased to 10 mg in April. No breathlessness. Mild pitting oedema to mid-shin. BP 138/84. Amlodipine stopped because of ankle oedema; switched to lercanidipine 10 mg OD. Review in 4 weeks.
Northfield Pathology (fictional) · received 3 Jun 2026 15:48
U&E: Na 140 mmol/L, K 4.7 mmol/L, creatinine 124 µmol/L, eGFR 56 mL/min/1.73m² · no laboratory flag
Northfield Pathology (fictional) · received 3 Jun 2026 15:48
Urine albumin:creatinine ratio 38 mg/mmol · flagged H by the laboratory
Dr S. PATEL
Amlodipine increased from 5 mg to 10 mg once daily.
K. AHMED
Structured medication review. Taking amlodipine 5 mg, ramipril 10 mg and atorvastatin 20 mg as prescribed. Home BP average 146/88. No side effects reported. Next medication review 14 Nov 2026.
Northfield Pathology (fictional) · received 14 Nov 2025 16:05
Lipid profile: total cholesterol 4.1 mmol/L, LDL cholesterol 2.0 mmol/L · no laboratory flag
Amlodipine 5 mg once daily started. Indication: hypertension.
Atorvastatin 20 mg at night started. Indication: hypercholesterolaemia.
Codeine — nausea and vomiting (intolerance)
U&E at least every 12 months while on an ACE inhibitor or angiotensin receptor blocker.
U&E at least every 12 months while on dapagliflozin; an earlier test requested in specialist correspondence is followed as written.
ALT within 3 months and at 12 months after starting a statin.
Illustrative demonstration · intended workflow · Scripted reconstruction: the development build itself is not running on this page.
- Each medicine shown with its indication, recent changes and monitoring.
- Open items come from the record: overdue tests, unactioned letter instructions.
- The clinician edits the brief and records the review in their name.
From what arrives to what you decide
- What entersMedicines, indications, results, allergies, letters and monitoring
- What Reedley preparesOne structured brief, every line with its source
- What the clinician decidesYou edit the brief, write the review and record it as yours
What it does not do · what exists today
- The brief contains no prescribing suggestions.
- No interaction or dose checking is performed.
- The review brief is an illustration of intended workflow. It builds on Patient Context, which is in the development build.
- Not yet in Reedley’s intended-purpose register: shown to explore the workflow, not as committed product scope.
Every patient shown is synthetic. No integration with a clinical system is claimed, and no clinician has yet used Reedley in practice. Safety and governance
See it with your own work in mind.
Tell us your role and the workflows you care about, and we will walk you through them on synthetic data.